Actuate Therapeutics , Inc., a biopharmaceutical company with a market capitalization of $172 million, announced today that it will hold its first Annual Meeting of Stockholders virtually on May ...

Sigma Planning Corp bought a new position in shares of Actuate Therapeutics (NASDAQ:ACTU – Free Report) during the 4th quarter, according to the company in its most recent filing with the ...

Actuate Therapeutics (ACTU) announced the completion of patient enrollment in the ongoing Phase 2 trial of FOLFIRINOX in combination with ...

Given this risk, we thought we'd take a look at whether Actuate Therapeutics (NASDAQ:ACTU) shareholders should be worried about its cash burn. In this article, we define cash burn as its annual ...

CHICAGO and FORT WORTH, Texas - Actuate Therapeutics, Inc. (NASDAQ: ACTU), a clinical-stage biopharmaceutical company with a market capitalization of $152 million, has announced the completion of ...

Riley representative to request a one-on-one meeting with management. About Actuate Therapeutics, Inc. Actuate is a clinical-stage biopharmaceutical company focused on developing therapies for the ...

Richard Stark is the director of Financial Performance Management Solutions at Actuate Corporation. He is responsible for shaping product direction and market strategy. For 20 years, Stark has been a ...

Financials are currently not available. Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.